BACKGROUND: Patient reported outcome measures used in studies of psoriatic arthritis (PsA) have been found to be inadequate for determining the impact of the disease from the patient's perspective. OBJECTIVE: To produce the PsAQoL, a PsA-specific quality of life (QoL) instrument, employing the needs based model of QoL that would be relevant and acceptable to respondents, valid, and reliable. METHODS: Content was derived from qualitative interviews conducted with patients with PsA. Face and content validity were assessed by field test interviews with a new sample of patients with PsA. A postal survey was conducted to improve the scaling properties of the new measure. Finally, a test-retest postal survey was used to identify the final measure and to test its scaling properties, reliability, internal consistency, and validity. RESULTS: Analysis of the qualitative interview transcripts identified a 51 item questionnaire. Field test interviews confirmed the acceptability and relevance of the measure. Analysis of data from the first postal survey (n = 94) reduced the questionnaire to 35 items. Rasch analysis of data from the test-retest survey (n = 286) identified a 20 item version of the PsAQoL with good item fit. This version had excellent internal consistency (alpha = 0.91), test-retest reliability (0.89), and validity. CONCLUSIONS: The PsAQoL is a valuable tool for assessing the impact of interventions for PsA in clinical studies and trials. It is well accepted by patients, taking about three minutes to complete, is easy to administer, and has excellent scaling and psychometric properties.
BACKGROUND:Patient reported outcome measures used in studies of psoriatic arthritis (PsA) have been found to be inadequate for determining the impact of the disease from the patient's perspective. OBJECTIVE: To produce the PsAQoL, a PsA-specific quality of life (QoL) instrument, employing the needs based model of QoL that would be relevant and acceptable to respondents, valid, and reliable. METHODS: Content was derived from qualitative interviews conducted with patients with PsA. Face and content validity were assessed by field test interviews with a new sample of patients with PsA. A postal survey was conducted to improve the scaling properties of the new measure. Finally, a test-retest postal survey was used to identify the final measure and to test its scaling properties, reliability, internal consistency, and validity. RESULTS: Analysis of the qualitative interview transcripts identified a 51 item questionnaire. Field test interviews confirmed the acceptability and relevance of the measure. Analysis of data from the first postal survey (n = 94) reduced the questionnaire to 35 items. Rasch analysis of data from the test-retest survey (n = 286) identified a 20 item version of the PsAQoL with good item fit. This version had excellent internal consistency (alpha = 0.91), test-retest reliability (0.89), and validity. CONCLUSIONS: The PsAQoL is a valuable tool for assessing the impact of interventions for PsA in clinical studies and trials. It is well accepted by patients, taking about three minutes to complete, is easy to administer, and has excellent scaling and psychometric properties.
Authors: Anabela Barcelos; Catarina Ambrósio; J A Pereira da Silva; Stephen McKenna; Jeanette Wilburn; Pedro Lopes Ferreira Journal: Rheumatol Int Date: 2017-10-30 Impact factor: 2.631
Authors: Jeanette Wilburn; Stephen P McKenna; Şehim Kutlay; Tamas Bender; Jürgen Braun; Concepcion Castillo-Gallego; Marta Favero; Pal Geher; Uta Kiltz; Emilio Martin-Mola; Roberta Ramonda; Matthew Rouse; Alan Tennant; Ayşe A Küçükdeveci Journal: Rheumatol Int Date: 2017-02-15 Impact factor: 2.631
Authors: Donna Coffin; Karine Duval; Simon Martel; John Granton; Marie-Claude Lefebvre; David M Meads; James Twiss; Stephen P McKenna Journal: Can Respir J Date: 2008-03 Impact factor: 2.409
Authors: Valentin Brodszky; Péter Bálint; Pál Géher; László Hodinka; Gábor Horváth; Éva Koó; Márta Péntek; Anna Polgár; Magdolna Seszták; Sándor Szántó; Ilona Ujfalussy; László Gulácsi Journal: Rheumatol Int Date: 2009-12 Impact factor: 2.631